Search

Membership

Change the world. Make a difference. Improve the lives of many. With more than 6,000 members from 150 countries, EHA is the largest European-based organization that caters to medical professionals, researchers, and scientists with an active interest in hematology.

Read more

Major research funding calls are out now

First, the Innovative Medicines Initiative published its final call under the EU Seventh Framework Programme. Interestingly for hematologists, the call includes a project called ‘Blood-based biomarker assays for personalized tumour therapy: value of circulating biomarkers’.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Stem Cells

Mission:

The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.

Read more

EHA-ISHBT Hematology Tutorial on Lymphoproliferative and Plasma Cell Disorders

EHA Hematology Tutorial in collaboration with the Indian Society of Hematology & Blood Transfusion

Dates: February 16-18, 2018
Location: Lucknow, India
Chairs: AK Tripathi & G Gaidano

Goal of the meeting
This three day event aims to increase the knowledge of participants on how to provide…

Read more

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more